Effect of Monoclonal Anti-IL6 Antibody (Tocilizumab) on the Cardiovascular Risk in Patients With Rheumatoid Arthritis.[Efecto del anticuerpo monoclonal anti-IL6 (tocilizumab) en el riesgo cardiovascular de los pacientes con artritis reumatoide.]

Trial Profile

Effect of Monoclonal Anti-IL6 Antibody (Tocilizumab) on the Cardiovascular Risk in Patients With Rheumatoid Arthritis.[Efecto del anticuerpo monoclonal anti-IL6 (tocilizumab) en el riesgo cardiovascular de los pacientes con artritis reumatoide.]

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Feb 2017

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms TOCRIVAR
  • Most Recent Events

    • 15 Jul 2016 Planned primary completion date changed from 1 Apr 2013 to 1 Mar 2017.
    • 15 Jul 2016 Status changed from recruiting to active, no longer recruiting.
    • 19 Dec 2012 Planned end date changed from 5 Dec 2012 to 1 Apr 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top